Variations of this system have been used in most KDOQI and all KDIGO guidelines and have been recommended by the US Agency for Healthcare Research and Quality Evidence-based Practice Center program.107 Each study was given an overall quality grade based on its design, methodology (randomization, allocation, blinding, definition of outcomes, appropriate use of statistical methods, etc.), conduct (dropout percentage, outcome assessment methodologies, etc.) and reporting (internal Table 9 | Work products for the guideline* Topic Summary table of RCTs Evidence profile Lipid-lowering agents or diet/lifestyle modification Atorvastatin vs. atorvastatin + (single study) Ezetimibe vs. placebo (simvastatin+ezetimibe vs. simvastatin) + (single study) Statin vs. placebo in ADPKD + (single study) Statin vs. placebo in CKD + + (8 studies) Statin vs. usual care + (single study) Low vs. moderate protein diet + (single study) Statin + ezetimibe vs. placebo + (single study) Statin vs. placebo in kidney transplant recipients + + (2 studies) Statin vs. lifestyle in kidney transplant recipients + + (2 studies) Statin vs. placebo in children + (single study) Statin vs. placebo in CKD with dialysis + + (2 studies) Exercise vs. control + (single study) Drug interactions (update of Tables 32 37 in KDOQI 2003 guideline) Drug interactions + (single pre-existing systematic review) Adverse events from statin+fibrate therapy Any adverse event + (no evidence profiles prepared re adverse events) Serious adverse event + (no evidence profiles prepared re adverse events) Treatment-related adverse event + (no evidence profiles prepared re adverse events) Discontinuation due to adverse event + (no evidence profiles prepared re adverse events) Increased ALT or AST + (no evidence profiles prepared re adverse events) Increased creatine kinase + (no evidence profiles prepared re adverse events) Increased SCr + (no evidence profiles prepared re adverse events) Rhabdomyolysis + (no evidence profiles prepared re adverse events) Other adverse event + (no evidence profiles prepared re adverse events) Frequency of lipids testing Frequency of lipids testing (0 studies) Change in LDL-C by statin Change in LDL-C by statin + (single pre-existing systematic review) Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CKD, chronic kidney disease; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled trial; SCr, serum creatinine. 